The world's second-largest drugmaker says its Xeljanz has been approved in Russia, Argentina, Kuwait, the United Arab Emirates and Switzerland, the first European country to allow sales.
Meanwhile, New York-based Pfizer is asking advisers to European Union medical regulators to reconsider their recommendation not to approve the drug.
The advisers said Xeljanz didn't control progression of the immune disorder enough to outweigh serious side effects seen in some patients. Those include blood and other cancers, perforated intestines, tuberculosis and other infections, decreased infection-fighting cells, headaches and diarrhea.
Xeljanz, the first in a new class of drugs, was launched in the U.S. in November. It has been heavily advertised.
MORE HBJ HEADLINES
Our new comment system is not supported in IE 7. Please upgrade your browser here.